Newsroom

Industry News

19 Jun

Prima BioMed (PBMD) to Present at 2014 WAGO Annual Meeting

Prima BioMed Ltd (ASX: PRR) (NASDAQ:PBMD) (“Prima”, “the Company”) today advised that the Western Association of Gynecologic Oncologists (WAGO) Program Committee has accepted the abstract entitled “Treatment with Mucin 1-Autologous Dendritic Cell Therapy Significantly Improves Progression-Free Survival in Ovarian Cancer Patients in Second Remission” for oral presentation at the...

Read more

17 Jun

Inovio Pharmaceuticals (INO) Broadens its Intellectual Property Portfolio from the University of Pennsylvania

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research agreement with the university to...

Read more

16 Jun

Arch Therapeutics (ARTH) Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr....

Read more

16 Jun

Stevia First Corp. Accelerates Commercialization With Launch of SF Pure $STVF

Stevia First Corp. (OTCQB: STVF) (“Stevia First” or the “Company”), an agricultural biotechnology company based in California’s Central Valley growing region and focused on the industrial scale production of stevia, the all-natural zero-calorie sweetener that is rapidly transforming the food and beverage industry, is pleased to announce that it...

Read more

16 Jun

Inovio Pharmaceuticals (INO) to Present at Upcoming Healthcare Conferences

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President & CEO, Dr. J. Joseph Kim, will participate in a panel at the Piper Jaffray GenomeRx Symposium on June 23 to discuss Inovio’s leadership in the advancement of novel DNA-based immune therapies. Inovio management will also present a corporate...

Read more

12 Jun

Cesca Therapeutics (KOOL) Announces Proposed Public Offering

Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, announced today that it intends to offer Units consisting of its shares of common stock and warrants to purchase shares of common stock in an underwritten public offering. The shares of common stock and warrants comprising the units are...

Read more

11 Jun

Celator (R) Pharmaceuticals Announces Data and Safety Monitoring Board Recommendation to Continue Phase 3 Study of CPX-351

Celator Pharmaceuticals, Inc. (CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred...

Read more

Page 215 of 222« First...102030...213214215216217...220...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address